journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Hematology

journal
https://www.readbyqxmd.com/read/30430419/risk-factors-and-timing-of-autologous-stem-cell-transplantation-for-patients-with-peripheral-t-cell-lymphoma
#1
Satoshi Yamasaki, Dai Chihara, Sung-Won Kim, Takahito Kawata, Shuichi Mizuta, Hiroatsu Ago, Takaaki Chou, Takahisa Yamane, Hitoji Uchiyama, Tatsuo Oyake, Katsuhiro Miura, Bungo Saito, Hirofumi Taji, Hirohisa Nakamae, Toshihiro Miyamoto, Takahiro Fukuda, Junya Kanda, Yoshiko Atsuta, Ritsuro Suzuki
High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015...
November 14, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30406907/characteristics-and-prognosis-of-patients-with-non-immunoglobulin-m-monoclonal-gammopathy-of-undetermined-significance-a-retrospective-study
#2
Chihiro Kuwabara, Yukie Sakuma, Ayaka Kume, Yuri Tamura, Ryo Shimizu, Rie Iwai, Akihiro Ishii, Hiroaki Tanaka
Non-immunoglobulin (Ig)-M monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion with the potential to evolve into a malignant plasma cell neoplasm. The prevalence of MGUS differs by ethnicity and is lower in the Japanese population than in the Western population. However, there is limited evidence about the clinical course of MGUS in Asian races. The present study aims at elucidating the clinical course and prognosis of Japanese patients with non-IgM MGUS in the clinical setting. We retrospectively examined 1009 patients with non-IgM MGUS identified by screening procedures...
November 8, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30406327/correction-to-a-phase-ii-study-of-lenalidomide-consolidation-and-maintenance-therapy-after-autologous-pbsct-in-patients-with-multiple-myeloma
#3
Shin-Ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, Hirokazu Okumura, Tohru Murayama, Toshihiro Miyamoto, Eichi Otsuka, Naohito Fujishima, Tohru Izumi, Shigehisa Tamaki, Yasushi Hiramatsu, Yoshiaki Kuroda, Chihiro Shimazaki, Koichi Akashi, Mine Harada
In the original publication of this article, "Conflict of interest" was published incorrectly. The corrected "Conflict of interest" is given below for your reading.
November 7, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30406326/correction-to-systematic-review-of-pre-clinical-chronic-myeloid-leukaemia
#4
Jew Win Kuan, Anselm Ting Su, Chooi Fun Leong, Motomi Osato, Goro Sashida
The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading.
November 7, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30386961/presacral-extramedullary-hematopoiesis-under-treatment-with-an-erythropoietin-stimulating-agent-for-myelodysplasia
#5
LETTER
Tatsuya Konishi, Noriko Doki, Yasunobu Takaki, Aiko Igarashi, Kazuteru Ohashi
No abstract text is available yet for this article.
November 1, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30368656/epstein-barr-virus-related-diffuse-large-b-cell-lymphoma-in-mogamulizumab-treated-adult-t-cell-leukemia-with-incomplete-t-cell-reconstitution
#6
Kazuharu Kamachi, Takero Shindo, Masaharu Miyahara, Kazutaka Kitaura, Michiaki Akashi, Tadasu Shin-I, Ryuji Suzuki, Koichi Oshima, Shinya Kimura
Adult T-cell leukemia (ATL) is an aggressive mature T-cell malignancy with a poor prognosis. The anti-C-C motif chemokine receptor 4 (CCR4) antibody mogamulizumab (moga) reduces ATL cells and induces reconstitution of polyclonal T cells; however, ATL cases often remain resistant and moga sometimes causes fatal immunopathology. Epstein-Barr virus (EBV)-related B-cell lymphoma develops in severely immunocompromised subjects, and is particularly associated with impaired T-cell immunity. Here, we report an ATL patient who had received conventional chemotherapy plus moga, and subsequently developed EBV-related diffuse large B-cell lymphoma (DLBCL) of the central nervous system...
October 27, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30361829/a-case-of-recurrent-histiocytic-sarcoma-with-map2k1-pathogenic-variant-treated-with-the-mek-inhibitor-trametinib
#7
Tadashi Kumamoto, Yuki Aoki, Tomoko Sonoda, Miho Yamanishi, Ayumu Arakawa, Masanaka Sugiyama, Nami Shirakawa, Sae Ishimaru, Yoshimasa Saito, Akiko Maeshima, Miho Maeda, Chitose Ogawa
Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai-Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma...
October 25, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30353275/molecular-pathogenesis-of-leukemia-and-leukemic-stem-cells-lscs
#8
EDITORIAL
Masahiro Kizaki
No abstract text is available yet for this article.
October 23, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30350119/emicizumab-a-humanized-bispecific-antibody-to-coagulation-factors-ixa-and-x-with-a-factor-viiia-cofactor-activity
#9
REVIEW
Takehisa Kitazawa, Midori Shima
Hemophilia A is a congenital disorder caused by deficiency or malfunction of coagulation factor (F) VIII. While exogenously provided FVIII effectively reduces bleeding complications in many hemophilia A patients, multiple efforts are underway to develop new drugs to meet the needs that conventional FVIII agents do not. We have been long engaged in creating and clinically developing a humanized anti-FIXa/FX asymmetric bispecific IgG antibody with a FVIIIa-cofactor activity. Since this project was born from a creative and unique idea, our group recognized from the first that it would face many difficulties in the course of research including establishment of industrial manufacturability of an asymmetric bispecific IgG antibody...
October 22, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30327925/late-stage-myeloma-invades-kidney-without-significant-effect-on-renal-function-findings-from-53-autopsies-in-a-single-institute
#10
Junichiro Takano, Sohtaro Mine, Makoto Mochizuki, Noriko Tanaka, Shotaro Hagiwara
Renal manifestations of multiple myeloma (MM) including cast nephropathy, amyloidosis, and renal calcification have been widely recognized. However, the severity of histopathological findings has not been addressed so far, and the clinical significance of these pathological findings is unclear. We sought to clarify the relationship between the severity of renal pathology and clinical characteristics. We analyzed 53 autopsies performed on patients who died from MM. The kidneys were evaluated using light microscopy, and the severity of pathological findings was recorded...
October 16, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30311142/immunoparesis-in-symptomatic-multiple-myeloma-at-diagnosis-affects-pfs-with-bortezomib-containing-induction-therapy-but-not-asct-consolidation
#11
Wen Gao, Jie Li, Yuan Jian, Guangzong Yang, Yin Wu, Yanchen Li, Yun Len, Aijun Liu, Ying Tian, Huijuan Wang, Huixing Zhou, Zhiyao Zhang, Wenming Chen
In novel agent era, the impact of immunoparesis at diagnosis on outcomes in symptomatic multiple myeloma (MM) remains unclear. We reviewed medical records of 147 MM patients at Beijing Chao Yang hospital. Most patients exhibited immunoparesis at diagnosis (84%). After a median follow-up of 27 months (range 1-78 months), in the group with immunoparesis at diagnosis, there was a very significantly shorter progression-free survival (PFS) than in the group without immunoparesis (estimated PFS of not reached vs 25 months, P = 0...
October 11, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30302740/anti-tissue-factor-pathway-inhibitor-tfpi-therapy-a-novel-approach-to-the-treatment-of-haemophilia
#12
REVIEW
Pratima Chowdary
Novel approaches to the treatment of haemophilia are needed due to the limitations of the current standard of care, factor replacement therapy. Aspirations include lessening the treatment burden and effectively preventing joint damage. Treating haemophilia by restoring thrombin generation may be an effective approach. A promising target for restoring thrombin generation is tissue factor pathway inhibitor (TFPI), a multivalent Kunitz-type serine protease inhibitor that regulates tissue factor-induced coagulation via factor Xa-dependent feedback inhibition of the tissue factor-factor VIIa complex...
October 9, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30302739/risk-factors-and-survival-impact-of-readmission-after-single-unit-cord-blood-transplantation-for-adults
#13
Yasuko Yamagishi, Takaaki Konuma, Yoriko Miwa, Maki Oiwa-Monna, Susumu Tanoue, Masamichi Isobe, Koji Jimbo, Mai Mizusawa, Hatsuko Narita, Koji Kobayashi, Seiko Kato, Satoshi Takahashi, Arinobu Tojo
Hospital readmissions have been used as a prognostic indicator for patients receiving allogeneic hematopoietic cell transplantation (HCT). However, the impact of readmission during early and mid-phase of cord blood transplantation (CBT) on long-term outcomes has not been fully investigated. We retrospectively analyzed 156 adult patients who received single-unit CBT in our institute. Among this cohort, thirteen patients (8%) were readmitted within 30 days after discharge, and 27 (17%) were readmitted within 90 days after discharge...
October 9, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30293217/massive-bone-marrow-necrosis-revealing-an-hiv-related-primary-bone-marrow-lymphoma-a-diagnostic-challenge
#14
Michael D Diamantidis, Vasiliki Gogou, Triantafyllia Koletsa, Simeon Metallidis, Maria Papaioannou
Bone marrow necrosis (BMN) is a condition that can be difficult to diagnose, requiring a hematologist experienced in bone marrow morphology. This diagnostic challenge should alert the clinician of a severe disease or a possible underlying malignancy, either hematological or a solid tumor. We describe the concomitant presence of a primary bone marrow lymphoma (diffuse large B-cell lymphoma-DLBCL), along with an extensive BMN in an HIV patient for the first time in a living individual. HIV infection, BMN and DLBCL presented a multifactorial crossword of molecular events underlying the complex pathophysiology...
October 6, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30291558/venous-thromboembolism-in-relapsed-or-refractory-multiple-myeloma-patients-treated-with-lenalidomide-plus-dexamethasone
#15
Junghoon Shin, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jeong-Ok Lee, Cheolwon Suh, Jin Seok Kim, Yoo Jin Lee, Sung-Soo Yoon, Jae-Cheol Jo, Ho Sup Lee, Soo-Mee Bang
Lenalidomide plus dexamethasone (LD) is currently the mainstay of treatment for both untreated and relapsed or refractory multiple myeloma (RRMM). Although lenalidomide-associated venous thromboembolism (VTE) is a major clinical concern, its incidence and prognostic impact have not been delineated. In this nationwide retrospective cohort study, we aimed to determine the cumulative incidence of VTE and its prognostic value using two consecutive cohorts of LD-treated RRMM patients: the KMM151 cohort (N = 542) and the HIRA cohort (N = 1559)...
October 5, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30291557/cytomegalovirus-meningitis-in-a-patient-with-relapsed-acute-myeloid-leukemia
#16
Kaito Harada, Noritaka Sekiya, Shuntaro Ikegawa, Shugo Sasaki, Takeshi Kobayashi, Kazuteru Ohashi
Cytomegalovirus meningitis/meningoencephalitis is a potentially fatal complication following hematopoietic stem cell transplantation that causes significant morbidity and mortality. In the pre-transplant setting, a few cases involving lymphoid malignancies have been reported. However, there have been no reports of patients with myeloid malignancies. A 36-year-old man with relapsed acute myeloid leukemia received high-dose cytarabine-containing salvage chemotherapies and then developed grade 4 lymphopenia for more than one month...
October 5, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30284685/a-phase-ii-study-of-lenalidomide-consolidation-and-maintenance-therapy-after-autologous-pbsct-in-patients-with-multiple-myeloma
#17
Shin-Ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, Hirokazu Okumura, Tohru Murayama, Toshihiro Miyamoto, Eichi Otsuka, Naohito Fujishima, Tohru Izumi, Shigehisa Tamaki, Yasushi Hiramatsu, Yoshiaki Kuroda, Chihiro Shimazaki, Koichi Akashi, Mine Harada
The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy...
October 4, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30264284/what-do-the-lineage-tracing-studies-tell-us-consideration-for-hematopoietic-stem-cell-origin-dynamics-and-leukemia-initiating-cells
#18
REVIEW
Nathalia Azevedo Portilho, Michihiro Kobayashi, Momoko Yoshimoto
The recent advance of technologies enables us to trace the cell fate in vivo by marking the cells that express the gene of interest or by barcoding them at a single cell level. Various tamoxifen-inducible Cre-recombinase mice combined with Rosa-floxed lines are utilized. In this review, with the results revealed by lineage tracing assays, we re-visit the long-standing debate for the origin of hematopoietic stem cells in the mouse embryo, and introduce the view of native hematopoiesis, and possible leukemic-initiating cells emerged during fetal stages...
September 27, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30251131/risk-of-secondary-primary-malignancies-in-multiple-myeloma-patients-with-or-without-autologous-stem-cell-transplantation
#19
Satoshi Yamasaki, Goichi Yoshimoto, Kentaro Kohno, Hideho Henzan, Takatoshi Aoki, Kazuki Tanimoto, Yasuhiro Sugio, Tsuyoshi Muta, Tomohiko Kamimura, Yuju Ohno, Ryosuke Ogawa, Tetsuya Eto, Koji Nagafuji, Toshihiro Miyamoto, Koichi Akashi, Hiromi Iwasaki
Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively...
September 24, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30232784/deregulated-iron-metabolism-in-bone-marrow-from-adenine-induced-mouse-model-of-chronic-kidney-disease
#20
Tomoko Kimura, Takahiro Kuragano, Kiyoko Yamamoto, Masayoshi Nanami, Yukiko Hasuike, Takeshi Nakanishi
Although the primary cause of anemia in chronic kidney disease (CKD) is lack of sufficient erythropoietin (EPO), other factors may be involved, including the deregulation of iron metabolism. To clarify the mechanism of deranged erythropoiesis in CKD, we evaluated bone marrow (BM) cells in adenine-induced CKD mice. They showed even higher EPO expression in the kidney. Hepatic hepcidin mRNA and plasma hepcidin and ferritin levels were increased. Flow cytometry revealed a decrease in the number of cells expressing transferrin receptor (TfR), or late erythroid progenitors in BM; these cells correspond to proerythroblasts, and basophilic and polychromatic erythroblasts...
September 19, 2018: International Journal of Hematology
journal
journal
30826
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"